Cargando…
First-line treatment of advanced ALK-positive non-small-cell lung cancer
Non-small-cell lung cancer (NSCLC) is one of the leading causes of cancer deaths, both within the US and worldwide. There have been major treatment advances in NSCLC over the past decade with the discovery of molecular drivers of NSCLC, which has ushered in an era of personalized medicine. There are...
Autores principales: | Gandhi, Shipra, Chen, Hongbin, Zhao, Yujie, Dy, Grace K |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5217519/ https://www.ncbi.nlm.nih.gov/pubmed/28210152 http://dx.doi.org/10.2147/LCTT.S63491 |
Ejemplares similares
-
First line treatment of advanced non-small-cell lung cancer – specific focus on albumin bound paclitaxel
por: Gupta, Neha, et al.
Publicado: (2013) -
Identification of Epidermal Growth Factor Receptor Tyrosine-Kinase Mutations in Non-small Cell Lung Cancer: Testing Platform Matters
por: Gandhi, Shipra, et al.
Publicado: (2020) -
Spotlight on crizotinib in the first-line treatment of ALK-positive advanced non-small-cell lung cancer: patients selection and perspectives
por: Leprieur, Etienne Giroux, et al.
Publicado: (2016) -
A comprehensive clinical evaluation of first-line drugs for ALK-positive advanced non-small cell lung cancer
por: Wang, Wan-Qing, et al.
Publicado: (2023) -
Optimal first-line treatment for metastatic ALK+ non-small cell lung cancer—a narrative review
por: Chazan, Grace, et al.
Publicado: (2023)